BioSpace News Archive

TherapeuticsMD, Inc., an innovative, leading women’s healthcare company, reported financial results for the third quarter ended September 30, 2022.

MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, reported results for the quarter ended September 30, 2022, and highlighted recent corporate events.

Precision Optics Corporation, Inc., a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its first quarter fiscal year 2023.

Insulet Corporation, announced a Medical Device Correction for the Omnipod® 5 Automated Insulin Delivery System because of an issue with the Omnipod 5 Controller charging port and cable.

Micron Solutions, Inc. (OTCQB: MICR) (the “Company”) announced financial results for its third quarter ended September 30, 2022.

Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its results of operations and financial condition as of and for the three and nine months ended September30, 2022 and provided a business update.

Innovent Biologics, Inc. (Innovent) (HKEX: 01801) today announced that the first participant has been successfully dosed in a phase 3 clinical trial (GLORY-1) of mazdutide (Innovent R&D Code: IBI362), a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese adults with overweight or obesity.

Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”) announced today that the China National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for Nefecon for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of rapid disease progression.

Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) is pleased to announce that the U.S. Food and Drug Administration (“FDA”) has given the Company Investigational New Drug (“IND”) clearance related to the Company’s New Chemical Entity (“NCE”) Triptax™.

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced corporate updates and financial results for the third quarter ended September 30, 2022.